82 related articles for article (PubMed ID: 3783901)
1. Increased porphobilinogen deaminase activity in patients with malignant lymphoproliferative diseases. A helpful diagnostic test.
Lahav M; Epstein O; Schoenfeld N; Shaklai M; Atsmon A
JAMA; 1987 Jan; 257(1):39-42. PubMed ID: 3783901
[TBL] [Abstract][Full Text] [Related]
2. Evidence of abnormality of lymphocyte uroporphyrinogen synthase in family members of patients with lymphoproliferative diseases.
Lahav M; Epstein O; Schoenfeld N; Nemesh L; Shaklai M; Atsmon A
Cancer Lett; 1985 Jan; 25(3):305-10. PubMed ID: 3971346
[TBL] [Abstract][Full Text] [Related]
3. Porphobilinogen deaminase activity in malignant proliferative disorders of the lymphatic system and bone marrow.
Zawirska B; Usnarska-Zubkiewicz L; Gamian E
Patol Pol; 1993; 44(1):13-7. PubMed ID: 8488077
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte uroporphyrinogen synthase activity as a possible diagnostic aid in the diagnosis of lymphoproliferative diseases.
Epstein O; Lahav M; Schoenfeld N; Nemesh L; Shaklai M; Atsmon A
Cancer; 1983 Sep; 52(5):828-32. PubMed ID: 6871824
[TBL] [Abstract][Full Text] [Related]
5. [Significance of porphobilinogen deaminase analysis in clinical tests].
Sassa S
Nihon Rinsho; 1989 Dec; 48 Suppl():711-4. PubMed ID: 2621989
[No Abstract] [Full Text] [Related]
6. [Lymphocyte uroporphyrinogen synthase in the diagnosis of lymphoma and its follow-up].
Lahav M; Epstein O; Schoenfeld N; Shaklai M; Atsmon A
Harefuah; 1985 Mar; 108(5):243-5. PubMed ID: 4007683
[No Abstract] [Full Text] [Related]
7. Erythrocyte porphobilinogen deaminase activity in liver diseases and proliferative diseases of the haemopoietic system and lymph nodes.
Ostrowski J; Lutyński A; Cianciara J; Martyńska M; Kostrzewska E; Butruk E
Mater Med Pol; 1987; 19(4):234-7. PubMed ID: 3454831
[No Abstract] [Full Text] [Related]
8. Haem precursors and porphobilinogen deaminase in erythrocytes and lymphocytes of patients with acute intermittent porphyria.
Gross U; Jacob K; Frank M; Doss MO
Cell Mol Biol (Noisy-le-grand); 1997 Feb; 43(1):29-35. PubMed ID: 9074786
[TBL] [Abstract][Full Text] [Related]
9. Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer.
Leibovici L; Schoenfeld N; Yehoshua HA; Mamet R; Rakowsky E; Shindel A; Atsmon A
Cancer; 1988 Dec; 62(11):2297-300. PubMed ID: 3179945
[TBL] [Abstract][Full Text] [Related]
10. Increased activity of porphobilinogen deaminase in erythrocytes during attacks of acute intermittent porphyria.
Kostrzewska E; Gregor A
Ann Clin Res; 1986; 18(4):195-8. PubMed ID: 3789651
[TBL] [Abstract][Full Text] [Related]
11. Differences in the enzymatic profile in human lymphoid tumors.
Ubeira FM; Seoane R; de Solas Rafecas I
Rev Esp Oncol; 1984; 31(4):559-73. PubMed ID: 6400533
[TBL] [Abstract][Full Text] [Related]
12. Determination of erythrocyte hydroxymethylbilane synthase activity and its application for study of acute intermittent porphyria.
Lee FY; Hsiao KJ; Tsai YT; Lee SD; Wu SJ; Jeng HS
Taiwan Yi Xue Hui Za Zhi; 1988 Nov; 87(11):1029-35. PubMed ID: 3235962
[No Abstract] [Full Text] [Related]
13. [Porphobilinogen deaminase (PBGD)].
Kondo M
Nihon Rinsho; 1995 Feb; 53 Su Pt 1():891-4. PubMed ID: 8753580
[No Abstract] [Full Text] [Related]
14. Immunological determination of porphobilinogen deaminase as a diagnostic measure in acute intermittent porphyria.
Lannfelt L
J Clin Chem Clin Biochem; 1990 May; 28(5):273-8. PubMed ID: 2380662
[TBL] [Abstract][Full Text] [Related]
15. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of biologic tests in malignant hemopathies].
Clément F
Schweiz Med Wochenschr; 1983 Jul; 113(26):948-51. PubMed ID: 6612275
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell porphobilinogen deaminase in the evaluation of acute intermittent porphyria.
Pierach CA; Weimer MK; Cardinal RA; Bossenmaier IC; Bloomer JR
JAMA; 1987 Jan; 257(1):60-1. PubMed ID: 3783903
[TBL] [Abstract][Full Text] [Related]
18. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
19. Effect of lead on the activity of erythrocyte porphobilinogen deaminase in vivo and in vitro.
Tomokuni K; Ichiba M
Toxicol Lett; 1990 Feb; 50(2-3):137-42. PubMed ID: 2309232
[TBL] [Abstract][Full Text] [Related]
20. [Lymphoid cell glycosidases in various forms of lymphoproliferative disorders].
Ushakova NA; Vlasova AL; Preobrazhenskaia ME; Samoĭlova RS; Polianskaia AM; Grigor'eva MA; Baĭdurin SA
Vopr Med Khim; 1991; 37(6):78-82. PubMed ID: 1812621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
